Oneness Biotech
4743Taipei, Taiwan· Est.
Taiwanese biotech delivering Phase 3 wound‑care therapy and a diversified pipeline across dermatology, immunology and metabolism.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwanese biotech delivering Phase 3 wound‑care therapy and a diversified pipeline across dermatology, immunology and metabolism.
DermatologyImmunologyInfectious DiseasesMetabolismWound Care
Technology Platform
In‑house discovery platform combining high‑throughput phenotypic screening, proprietary formulation science, and mechanistic studies to develop small‑molecule and biologic candidates.
Opportunities
Regulatory approval of ON101 could generate early revenue and enable expansion into Southeast Asian DFU markets; a diversified pipeline offers multiple avenues for growth.
Risk Factors
Reliance on a single late‑stage product for initial cash flow, competitive wound‑care landscape, and execution risk in advancing early‑stage candidates.
Competitive Landscape
Oneness competes with global wound‑care leaders such as Smith & Nephew and Mölnlycke, while its dermatology and immunology candidates face competition from large pharma; its proprietary formulation platform provides differentiation.